Karyopharm Therapeutics (KPTI) Receiving Somewhat Critical Press Coverage, Analysis Finds

News coverage about Karyopharm Therapeutics (NASDAQ:KPTI) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a news sentiment score of -0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 86 out of 100, indicating that recent news coverage is very likely to have an impact on the stock’s share price in the immediate future.

Several research firms have recently commented on KPTI. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a report on Friday, March 17th. Zacks Investment Research raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 21st. Robert W. Baird reissued an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 25th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, April 7th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.56.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded down 0.11% on Wednesday, hitting $9.51. The stock had a trading volume of 5,471 shares. The firm’s 50-day moving average is $9.29 and its 200 day moving average is $10.20. The stock’s market cap is $448.09 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.04. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.02 million. Karyopharm Therapeutics had a negative net margin of 50,646.40% and a negative return on equity of 72.41%. During the same quarter last year, the business posted ($0.75) earnings per share. Equities analysts forecast that Karyopharm Therapeutics will post ($2.68) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/karyopharm-therapeutics-kpti-earns-daily-media-impact-rating-of-0-12-updated/1115008.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.